Slide 1: A Review of Initial Phase 2 Patient Results & Future Directions for NSCLC Treatment in Never-Smokers
m™MNArMoaonic A Review of Initial Phase 2 Patient Results & Future Directions for NSCLC Treatment in Never-Smokers The Harmonic™ Trial -- Supporting Material for Release of Initial Clinical Data from First Cohort (n = 7) Dr. R. Ewesuedo, K. Bhatia, PhD, FRCP, & G. Agnello, PhD, D. Margrave and P. Sh
Slide 2: Forward-Looking Statements
wnarmonic Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, st
Slide 3: Schema of LP-300 Phase 2 Open Label, Randomized Clinical Study Design
YANAFMONIC — Schema of LP-300 Phase 2 Open Label, Randomized Clinical Study Design Arm A LP-300 + (Carboplatin + Pemetrexed) Safety Lead-in with Stratification (gender, N=56 Afte LP-300 + chemotherapy ig ) 4 ane Pemetrexed Ne7 2:1 Randomization Arm B cycles Maintenance SOC = Carboplatin + Pemetrexed
Slide 4: Clinical Trial Sites - The Harmonic Phase 2 Trial for LP-300
wANALMONIC _ Clinical Trial Sites - The Harmonic™ Phase 2 Trial for LP-300 I United States* = Initial Lead in Cohort (n=7) Fairfax, VA * Fountain Valley, CA +Dallas, TX 15-20% of NSCLC new cases are in . . never smokers * Philadelphia, PA +Los Angeles, CA Beverly Hills, CA Harmonic™ Clinical trial i
Slide 5: Safety Lead-in for Phase 2 Clinical Trial, Summary
wANarmMonic _ Safety Lead-in for Phase 2 Clinical Trial, Summary No Dose Limiting Toxicities or Serious Adverse Events were observed & Lantern received approval from the DSMB (Data & Safety Monitoring Board) to proceed to next phase of the trial e Overall, LP-300 in combination with the chemo double
Slide 6: Initial Cohort / Lead-in Phase - Summary Results & Key Takeaways
*NALMONIC _ initial Cohort / Lead-in Phase - Summary Results & Key Takeaways KEY PATIENT CHARACTERISTICS Tumor cd Response Carboplatin + Pemetrexed v Patients who are never smokers with lung Partial Response: 3/7 (43%) cancer and histopathological evidence of Stable Disease 3/7 (43%) stage III or IV
Slide 7: Percent change in cancer lesion size over time
WMANALMONIC | Harmonic™ Clinical Trial - Percent change in cancer lesion size over time Data from 6 out of 7 patients showing clinical benefit in initial lead-in cohort 60 40 20 Aten eeeeeeneeeneeenereeeeeeeeneeeeeeeeeeeenneeeeeeee seeeeerseeeeeee PP) Progressive Disease Cutoff Patients 107-003 \ 11
Slide 8: Percent change in cancer lesion size by patient
wharmonic Harmonic™ Clinica! Trial — Percent change in cancer lesion size by patient o o Data from 6 out of 7 patients showing clinical benefit in initial lead-in cohort No o °o seuaseeneseseesscesedsesessedensceseesesseesss*PPD) progressive Disoase Cutof +4% -18% -20% 46% -51% -57% eveaperaneeabawe
Slide 9: Initial patient cohort response over time
YNAFMONIC | Harmonic™ Clinical Trial - Initial patient cohort response over time Initial patient responses in the Harmonic™ trial include an 86% disease control rate in the cohort of lead-in patients and a 43% objective response rate (ORR) including one patient maintaining a 50+% reduction in tumor
Slide 10: Patient Demographics And Tumor Response Evaluation
wANarMonic Patient Demographics And Tumor Response Evaluation SUBJECT 107-002 Known mutations / biomarkers of interest EGFR MSI high not detected 107-003 EGFR L858R, MSI Stable TMB 3.4/Mb (Low) 110-001 EGFR L858R MSI high not detected 103-001 EGFR (GOF) TMB 7.9/Mb (intermediate) PD-L1 (IHC) 30% TPS
Slide 11: Initial Cohort - Prior cancer treatments / history & response
~ANALMONIC _ Initial Cohort for Phase 2 - Prior cancer treatments / history & response 107-002 107-003 110-001 103-001 110-002 110-003 110-004 Osimertinib Carboplatin Radiotherapy Osimertinib Osimertinib Selpercatinib Osimertinib Keytruda Alimta | | Radiotherapy Osimertinib Radiotherapy Radiotherapy
Slide 12: Initial Observations From Phase 2 Safety Lead-In Cohort
WMNALMONIC _ Initial Observations From Phase 2 Safety Lead-In Cohort " 7 patients enrolled, dosed and evaluated in lead-in phase of study, which is completed = 6 out of 7 patients have had clinical benefit = 3 are partial responses with an average tumor size reduction of ~51% = 3. are stable disease
Slide 13: Never Smokers Do Not Respond Well to Immunotherapy
vhnarmMonic Never Smokers Do Not Respond Well to Immunotherapy PD-1 Inhibitor Response by Smoking Status = Relative to smokers with NSCLC, never smokers are less likely to 255 have high expression of PD-L1, a key biomarker for immunotherapies; they are therefore much less likely to be eligible 2 204
Slide 14: Key Highlights of LP-300
w4narmonic Key Highlights of LP-300 LP-300 z mo LA, Il ° Lontorn ° ll S. ~~ jon 8 LP-300 is being investigated in a Phase 2 clinical trial, Harmonic™ in never smokers with NSCLC. ...-modulates receptor tyrosine kinases, DNA damage repair enzymes, and cellular redox processes ...possesses chemo-sensi
Slide 15: Appendix: Comparative & Benchmarking Data For NSCLC Patients Treated With Chemo Doublet
Appendix: Comparative & Benchmarking Data For NSCLC Patients Treated With Chemo Doublet
Slide 16: Historical Response Data For Pemetrexed + Carboplatin Arms
Historical Response Data For Pemetrexed + Carboplatin Arms in NSCLC Patients post TKI treatment STUDY ID (Sponsor) median ORR (%) (Carboplatin + Pemetrexed) median DOR (months) (Carboplatin + Pemetrexed) median PFS (months) (Carboplatin + Pemetrexed) Hazard Ratio (HR for PFS) (Carboplatin + Pemetrex